ZA200705231B - Use of oxycodone for treating visceral pain - Google Patents

Use of oxycodone for treating visceral pain

Info

Publication number
ZA200705231B
ZA200705231B ZA200705231A ZA200705231A ZA200705231B ZA 200705231 B ZA200705231 B ZA 200705231B ZA 200705231 A ZA200705231 A ZA 200705231A ZA 200705231 A ZA200705231 A ZA 200705231A ZA 200705231 B ZA200705231 B ZA 200705231B
Authority
ZA
South Africa
Prior art keywords
oxycodone
visceral pain
treating visceral
treating
pain
Prior art date
Application number
ZA200705231A
Other languages
English (en)
Inventor
Drewes Asbjorn Mohr
Nielsen Lars Arendt
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200705231(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ZA200705231B publication Critical patent/ZA200705231B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200705231A 2005-01-18 2007-07-02 Use of oxycodone for treating visceral pain ZA200705231B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
ZA200705231B true ZA200705231B (en) 2008-06-25

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705231A ZA200705231B (en) 2005-01-18 2007-07-02 Use of oxycodone for treating visceral pain

Country Status (32)

Country Link
US (2) US20080200493A1 (ja)
EP (1) EP1838318B1 (ja)
JP (1) JP5049139B2 (ja)
KR (10) KR20120089710A (ja)
CN (1) CN101106996B (ja)
AP (1) AP2249A (ja)
AR (1) AR052880A1 (ja)
AT (2) ATE446092T1 (ja)
AU (1) AU2006207498B2 (ja)
BR (1) BRPI0606247A2 (ja)
CA (1) CA2595043C (ja)
CY (1) CY1109660T1 (ja)
DE (2) DE202006019887U1 (ja)
DK (2) DK1838318T3 (ja)
EA (1) EA013544B1 (ja)
ES (1) ES2333901T3 (ja)
HK (1) HK1107933A1 (ja)
HR (1) HRP20090679T1 (ja)
IL (1) IL184530A (ja)
ME (1) ME01066B (ja)
MX (1) MX2007007207A (ja)
MY (1) MY144471A (ja)
NO (1) NO338968B1 (ja)
NZ (1) NZ555852A (ja)
PL (1) PL1838318T3 (ja)
PT (1) PT1838318E (ja)
RS (1) RS51069B (ja)
SI (1) SI1838318T1 (ja)
TW (1) TWI432196B (ja)
UA (1) UA85471C2 (ja)
WO (1) WO2006077212A1 (ja)
ZA (1) ZA200705231B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115333B (en) 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
ES2912569T3 (es) * 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
WO2012162243A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
WO2012162253A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
WO2020106735A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CA2250187A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
EP1838318A1 (en) 2007-10-03
CN101106996A (zh) 2008-01-16
EA013544B1 (ru) 2010-06-30
DK1838318T3 (da) 2010-01-04
DE202006019887U1 (de) 2007-07-26
SI1838318T1 (sl) 2010-02-26
AP2249A (en) 2011-07-18
JP5049139B2 (ja) 2012-10-17
AP2007004057A0 (en) 2007-08-31
ES2333901T3 (es) 2010-03-02
TWI432196B (zh) 2014-04-01
ATE446092T1 (de) 2009-11-15
KR20140091782A (ko) 2014-07-22
US20150190393A1 (en) 2015-07-09
AT9895U1 (de) 2008-05-15
AR052880A1 (es) 2007-04-11
RS51069B (sr) 2010-10-31
AU2006207498B2 (en) 2009-11-19
IL184530A (en) 2015-01-29
EP1838318B1 (en) 2009-10-21
WO2006077212A1 (en) 2006-07-27
KR20200128451A (ko) 2020-11-12
NO338968B1 (no) 2016-11-07
NO20074174L (no) 2007-10-17
DE602006009899D1 (de) 2009-12-03
KR20220165797A (ko) 2022-12-15
PT1838318E (pt) 2009-12-15
ME01066B (me) 2012-10-20
MY144471A (en) 2011-09-30
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
KR20190135557A (ko) 2019-12-06
EA200701541A1 (ru) 2008-02-28
DK200700207U1 (da) 2007-08-24
US20080200493A1 (en) 2008-08-21
HK1107933A1 (en) 2008-04-25
AU2006207498A1 (en) 2006-07-27
BRPI0606247A2 (pt) 2009-06-09
PL1838318T3 (pl) 2010-03-31
UA85471C2 (ru) 2009-01-26
KR20080106991A (ko) 2008-12-09
KR20120089710A (ko) 2012-08-13
US9271974B2 (en) 2016-03-01
CA2595043A1 (en) 2006-07-27
CA2595043C (en) 2013-11-19
NZ555852A (en) 2010-01-29
IL184530A0 (en) 2007-10-31
DK200700207U3 (da) 2007-09-28
KR20230170811A (ko) 2023-12-19
CY1109660T1 (el) 2014-08-13
KR20210131450A (ko) 2021-11-02
JP2008526927A (ja) 2008-07-24
CN101106996B (zh) 2013-10-23
HRP20090679T1 (hr) 2010-01-31
KR20070100368A (ko) 2007-10-10
TW200637554A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
HK1107933A1 (en) Use of oxycodone for treating visceral pain
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
IL248204A0 (en) Combined treatment of tumors expressing 38cd
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
IL188430A0 (en) Treatment of tumors
IL193460A0 (en) Compounds and methods for treatment of stroke
EP1838714A4 (en) METHODS OF TREATING PAIN
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
EP2219449A4 (en) METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
EP1928452A4 (en) USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
IL201422A0 (en) Therapeutic agents useful for treating pain
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0610868D0 (en) Treatment of pain
ZA200904478B (en) Novel therapeutic use for treating leukaemia
EP1813271A4 (en) PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN
GB0616450D0 (en) Treatment of pain
GB0623740D0 (en) Treatment of disease
EP1878443A4 (en) THERAPEUTIC AGENT FOR NEUROPATHIC PAIN
GB0408521D0 (en) Treatment of sepsis